
Please try another search
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
John L. Flavin | 54 | 2019 | Independent Chairman |
Christopher O’Donnell | 56 | 2021 | Member of Technical Advisory Board |
Anthony W. Tolcher | - | 2021 | Member of Clinical & Translational Medicine Advisory Board |
Lara S. Sullivan | - | 2019 | CEO, President, Chief Medical Officer & Director |
Jason J. Luke | - | - | Member of Clinical & Translational Medicine Advisory Board |
Morris Rosenberg | - | - | Chairperson of Technical Advisory Board |
Virgil Bryan Lawlis | - | - | Member of Technical Advisory Board |
Darren S. Cline | 61 | 2021 | Independent Director |
Rachel Wallach Humphrey | 64 | 2022 | Independent Director |
Robert Baffi | - | - | Member of Technical Advisory Board |
Michael Sun | - | - | Member of Technical Advisory Board |
Elliott M. Levy | 67 | 2023 | Member of Clinical & Translational Medicine Advisory Board |
Thomas Civik | 56 | 2021 | Independent Director |
Freda C. Lewis-Hall | 70 | 2021 | Independent Director |
Glenn A. Miller | - | 2023 | Member of Clinical & Translational Medicine Advisory Board |
Paul A. Bunn | - | 2023 | Member of Clinical & Translational Medicine Advisory Board |
Giulio Draetta | - | 2023 | Member of Clinical & Translational Medicine Advisory Board |
Jakob Dupont | 60 | 2023 | Independent Director |
Patricia LoRusso | - | 2023 | Member of Clinical & Translational Medicine Advisory Board |
Michael A. Metzger | 54 | 2024 | Independent Director |
Santhosh Palani | 41 | 2024 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review